文献速递神经核医学

基于分子影像的多系统萎缩脑葡萄糖代谢时空动态进展研究

Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-27

该研究回顾性纳入192名参与者(117例多系统萎缩患者和75名健康对照),利用[18F]FDG PET构建SuStaIn模型,识别出两种时空代谢进展亚型:亚型1以小脑起病为主,亚型2以纹状体起病为主,两亚型在认知、运动和DAT活性上存在差异,且SuStaIn分期与临床特征相关。

要点

  • 基于[18F]FDG PET的SuStaIn模型识别出两种多系统萎缩代谢进展亚型。
  • 亚型1富集于小脑型多系统萎缩,亚型2富集于帕金森型多系统萎缩。
  • 亚型1认知表现更差且纹状体DAT比值更低,亚型2运动障碍更明显。

核心结论

  • 本研究首次使用基于[18F]FDG PET的SuStaIn模型阐明多系统萎缩的时空动态进展,并识别出新的代谢亚型。
  • 这些发现为多系统萎缩的生物学异质性提供了代谢证据,可能有助于患者管理和机制理解。

研究设计与样本

  • 回顾性纳入192名参与者(117例多系统萎缩患者[70例MSA-P,47例MSA-C]和75名健康对照),均接受[18F]FDG PET扫描,其中82例多系统萎缩患者额外接受[18F]FP-CIT PET显像。
  • 利用横断面数据建立基于[18F]FDG PET的SuStaIn模型,以阐明脑葡萄糖代谢的时空演化模式并识别不同的代谢亚型。

主要发现

  • 基于[18F]FDG PET的SuStaIn模型识别出两种稳健的时空代谢进展亚型,亚型1富集于MSA-C(52.0%,39/75),亚型2富集于MSA-P(78.8%,26/33)。
  • 亚型1以最初小脑低代谢为特征,依次进展至脑干、纹状体和皮质区域;亚型2呈现纹状体起病模式,依次进展至脑干、小脑和额叶。
  • 尽管疾病持续时间相当,亚型1患者认知表现显著更差(MMSE,FDR q = 0.013;MoCA,FDR q = 0.032)且纹状体前-后壳核DAT比值降低(FDR q < 0.001),而亚型2患者运动障碍更明显(UPDRS-III,FDR q = 0.042)。
  • 在所有患者中观察到SuStaIn进展分期与临床特征显著相关,包括UPDRS-III(r = 0.322,p = 0.001)、MMSE(r = -0.263,p = 0.009)和MoCA评分(r = -0.292,p = 0.004)。
  • 这些结果在独立验证队列中得到确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with complex clinical manifestations, which is essential for patient management and mechanistic understanding of MSA. In this study, we aimed to use disease progression modeling (SuStaIn model) to elucidate the in vivo spatiotemporal progression patterns of brain glucose metabolism in MSA patients, and investigate the differential profiles of clinical characteristics and dopaminergic function among the identified progression-related subtypes. METHODS: A total of 192 participants (117 MSA patients [70 MSA-P, 47 MSA-C] and 75 healthy controls) who underwent [18F]FDG PET scans, with 82 MSA patients additionally receiving [18F]FP-CIT PET imaging were retrospectively enrolled. [18F]FDG PET-based SuStaIn model was established to illustrate spatiotemporal evolutionary patterns of brain glucose metabolism using the cross-sectional data, and identified distinct metabolic subtypes. Metabolic subtypes and stages were correlated with motor function (UPDRS-III), cognitive function (MMSE, MoCA), autonomic symptoms, and dopamine transporter (DAT) activity. RESULTS: The [18F]FDG PET-based SuStaIn model identified two robust spatiotemporal metabolic progression subtypes, with Subtype 1 enriched in MSA-C (52.0%, 39/75) and Subtype 2 in MSA-P (78.8%, 26/33). Subtype 1 was characterized by initial hypometabolism in the cerebellum, sequentially progressing to brainstem, striatum, and cortical regions. Subtype 2 demostrated a striatal-onset pattern, progressing sequentially to the brainstem, cerebellum, and frontal lobe. Despite comparable disease duration, subtype 1 patients exhibited significantly poorer cognitive performance (MMSE, FDR q = 0.013; MoCA, FDR q = 0.032) and reduced anterior-to-posterior putamen DAT ratios (FDR q < 0.001) compared to subtype 2. Conversely, subtype 2 patients showed more obvious motor deficits (UPDRS-III, FDR q = 0.042). Significant correlations were observed between SuStaIn progression stages and clinical features across all patients, including UPDRS-III (r = 0.322, p = 0.001), MMSE (r = -0.263, p = 0.009), and MoCA scores (r = -0.292, p = 0.004). These results were confirmed in an independent validation cohort. CONCLUSION: This study for the first time used [18F]FDG PET-based SuStaIn model to elucidate spatiotemporal dynamic progression of MSA, and identified novel metabolic subtypes. These findings provided metabolic evidence of the biological heterogeneity in MSA, which maybe helpful for patients managment and the understanding of mechanisms. CLINICAL TRIAL NUMBER: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Dou X, Wang J, Hu D, et al. Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40859026. doi:10.1007/s00259-025-07509-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。